Clinical Trial Detail

NCT ID NCT03961672
Title Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications

CLL/SLL

Therapies

Duvelisib

Age Groups: adult senior

No variant requirements are available.